跳转至内容
Merck
CN
  • In vivo contribution of serine proteases to the proteolytic activation of γENaC in aldosterone-infused rats.

In vivo contribution of serine proteases to the proteolytic activation of γENaC in aldosterone-infused rats.

American journal of physiology. Renal physiology (2012-07-27)
Kohei Uchimura, Yutaka Kakizoe, Tomoaki Onoue, Manabu Hayata, Jun Morinaga, Rika Yamazoe, Miki Ueda, Teruhiko Mizumoto, Masataka Adachi, Taku Miyoshi, Naoki Shiraishi, Yoshiki Sakai, Kimio Tomita, Kenichiro Kitamura
摘要

Aldosterone plays an important role in the regulation of blood pressure by modulating the activity of the epithelial sodium channel (ENaC) that consists of α-, β-, and γ-subunits. Aldosterone induces a molecular weight shift of γENaC from 85 to 70 kDa that is necessary for the channel activation. In vitro experiments demonstrated that a dual cleavage mechanism is responsible for this shift. It has been postulated that furin executes the primary cleavage in the Golgi and that the second cleavage is provided by other serine proteases such as prostasin or plasmin at the plasma membrane. However, the in vivo contribution of serine proteases to this cleavage remains unclear. To address this issue, we administered the synthetic serine protease inhibitor camostat mesilate (CM) to aldosterone-infused rats. CM decreased the abundance of the 70-kDa form of ENaC and led to a new 75-kDa form with a concomitant increase in the urinary Na-to-K ratio. Because CM inhibits the protease activity of serine proteases such as prostasin and plasmin, but not furin, our findings strongly indicate that CM inhibited the second cleavage of γENaC and subsequently suppressed ENaC activity. The results of our current studies also suggest the possibility that the synthetic serine protease inhibitor CM might represent a new strategy for the treatment of salt-sensitive hypertension in humans.